Muhammad Zia Ullah Khan adjusts a Petri dish under the glow of a fluorescence monitor, where tiny cells pulse like stars in a microchannel galaxy—each one a potential clue in the fight against cancer. At the Technical University of Munich (TUM), a team has unveiled CellTrap, a lab-on-a-chip platform that captures the intimate dance between immune cells and cancer cells with unprecedented clarity. Unlike traditional assays that deliver bulk averages, CellTrap reveals what happens in the quiet moments between individual cells: when contact sparks activation, and when activation leads to destruction. This level of detail could reshape how scientists understand immunotherapy, one of the most promising frontiers in oncology.
Immunotherapies work by empowering the body’s own immune system to recognize and destroy cancer cells. But their success varies widely—partly because cell-to-cell interactions are anything but uniform. Standard lab tests might tell researchers how many cancer cells survive after exposure to immune cells, but they miss the timing, sequence, and variability of individual encounters. CellTrap fills that gap. The device is a microfluidic chip with a central channel that splits into a network of 1,024 microscopic trapping chambers. Using fluid dynamics alone—no pumps or external instruments—cells are guided into these chambers, where they’re paired in controlled ratios and monitored for up to 14 hours via time-lapse microscopy. The entire system runs on a standard fluorescence microscope, making it accessible to labs worldwide.
In early experiments, the team used glioblastoma cells, an aggressive form of brain cancer, and watched as immune cells converged on their targets. They found that when multiple immune cells surrounded a single cancer cell, the attack was not only more frequent but also more intense. Crucially, they observed that early activation signals in immune cells—detected through fluorescence markers—often predicted later cancer cell damage. For the first time, researchers could trace a direct line from initial contact to final outcome within the same interaction. The platform was also tested on chronic myeloid leukemia and adenocarcinoma cells, confirming its versatility across cancer types.
"With CellTrap, we can not only measure whether immune cells kill cancer cells, but also track when and under what conditions this occurs," says Ghulam Destgeer, professor at TUM’s School of Computation, Information and Technology. The implications extend beyond cancer: the platform can host nearly any cell combination, opening doors for research in autoimmune diseases, infectious diseases, and regenerative medicine. As the team publishes their findings in RSC Advances, they emphasize simplicity and scalability—key to ensuring broad adoption. In a field where breakthroughs often demand billion-dollar labs, CellTrap proves that some of the most powerful insights can come from a small chip and a clear view.